Pharma Focus Asia
KP - Sustainable Packaging Solutions

Evonik Expands Dossenheim and Hanau Sites in Germany


Evonik has announced plans for the expansion of its Dossenheim and Hanau facilities in Germany in order to meet the increasing pharmaceutical demand for contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates in the European market.


With an investment of €25 million, the company is set to expand its facilities to increase the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates in Germany.

The expansion will support complex customer projects, associated with oncological, antiviral, and other specialised drug products.The projects typically involve advanced technologies, including continuous processing, catalysis, and cryogenic chemistry.

This project will enhance the company’s position as atop global contract manufacturing organisation for APIs and intermediates.

This expansion is a much needed project to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.

The first stage of the project is set to complete by middle of 2021, while the entire project is expected to be completed by 2024.


Budget€25 million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?